SLC25A2: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: SLC25A2

NCBI ID: G83884

SLC25A2

SLC25A2: A Potential Drug Target Or Biomarker for Various Diseases

SLC25A2 (MGC119151) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the solute carrier family 25 (SLC25) and is involved in the transport of different molecules across cell membranes. SLC25A2 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

SLC25A2 is a transmembrane protein that is expressed in the brain, heart, liver, and kidneys. It is a member of the SLC25 family, which includes several other proteins that are involved in the transport of different molecules across cell membranes. The SLC25 family is characterized by the presence of a transmembrane region, a cytoplasmic region, and an N-terminus that is involved in protein-protein interactions.

SLC25A2 is involved in the transport of various molecules across cell membranes, including water, ions, and organic molecules such as amino acids and nucleotides. It has been shown to be involved in a variety of physiological processes, including cell signaling, neurotransmission, and pharmacology.

SLC25A2 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, SLC25A2 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development and progression of cancer, including breast and ovarian cancer.

In addition to its potential as a drug target or biomarker, SLC25A2 is also of interest as a potential therapeutic agent for a variety of diseases. For example, SLC25A2 has been shown to be involved in the regulation of ion channels, which are involved in a variety of physiological processes, including muscle contractions and nerve function. Therefore, inhibiting SLC25A2 activity may be a potential way to treat a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

SLC25A2 is also of interest as a potential target for drug development for various psychiatric disorders, including depression and anxiety. Studies have shown that SLC25A2 is involved in the regulation of neurotransmitter release from neurons, which is involved in the symptoms of depression and anxiety. Therefore, inhibiting SLC25A2 activity may be a potential way to treat these disorders.

In conclusion, SLC25A2 is a protein that is involved in the transport of different molecules across cell membranes in various tissues throughout the body. It has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. In addition to its potential as a therapeutic agent, SLC25A2 is also of interest as a potential target for drug development for various psychiatric disorders. Further research is needed to fully understand the role of SLC25A2 in these diseases and to develop effective treatments.

Protein Name: Solute Carrier Family 25 Member 2

Functions: Mitochondrial transporter of the positively charged amino acids ornithine, lysine and arginine, and the neutral amino acid citrulline (PubMed:12807890). In addition, transports the basic amino acids histidine, homoarginine, and asymmetric dimethylarginine (aDMA), but not symmetric DMA, and the D-forms of lysine, arginine, ornithine and histidine (PubMed:26403849, PubMed:12807890). Functions by both counter-exchange and uniport mechanisms (PubMed:26403849)

The "SLC25A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets